Should I Buy BMRN? BMRN 2026 Analysis

Should You Buy BioMarin Pharmaceutical Inc (BMRN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

58.130

1 Day change

1.71%

52 Week Range

73.510

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Good buy right now for a near-term catalyst run: price is sitting just above the pivot (~57.0) with improving momentum, while multiple catalysts (earnings 2/24 AH + FDA/PDUFA timing late Feb) can support a pre-event bid.
Street is leaning bullish: multiple recent Buy/Overweight calls with $80–$100 targets suggest meaningful upside if sentiment improves post-Amicus.
Sentiment from options is risk-on (call-heavy, put-call low) and volume is elevated, consistent with traders positioning for upside.
Intellectia Proprietary Trading Signals
- AI Stock Picker: No signal on given stock today.
- SwingMax: No signal on given stock recently.

Technical Analysis

Trend/Momentum: MACD histogram positive and expanding (0.0119) → supports a mild bullish continuation bias.
RSI: RSI(6) 58.13 (neutral-to-slightly-bullish) → not overbought; still room to push higher.
Moving averages: Converging MAs → transition phase; breakouts can accelerate, but trend is not yet strongly established.
Key levels:
- Pivot: 56.999 (current pre-market 57.73 is slightly above → constructive)
- Resistance: 58.328 (R1) then 59.149 (R2) (near-term upside map)
- Support: 55.669 (S1) then 54.848 (S2)
Pattern-based forward odds (similar candlesticks): +2.16% next day, +2.25% next week, but -4.06% next month → favors a tactical/near-term long rather than a passive hold.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/Sentiment: Put-call ratios are low (OI PCR 0.52; Volume PCR 0.18) → options flow is bullish / call-skewed.
Activity: Today’s option volume 2,385 vs 30D average shows a large spike (~197.6% of average) → heightened interest ahead of events.
Volatility: 30D IV ~49.84 vs historical vol ~27.79, with IV percentile 94.33 → market is pricing a meaningful move; traders appear willing to pay up for exposure (often seen into earnings/FDA windows).
Open interest: Calls OI 26,545 vs Puts OI 13,817 → supports a bullish bias in positioning.

Technical Summary

Sell

Buy

Positive Catalysts

- Earnings catalyst: QDEC 2025 earnings on 2026-02-24 (After Hours); pre-event positioning can lift the stock.
- Regulatory catalyst: News notes a PDUFA date for Palynziq on Feb 28, 2026 → event-driven attention on BMRN.
- Guidance tone improving: news indicates BioMarin raised the lower end of 2025 revenue guidance to $3.15B and expects strong Voxzogo sales.
- Deal narrative: Amicus acquisition viewed as a sentiment catalyst by multiple analysts (potentially breaking the stock out of its range).
- Sector tailwinds: Barclays commentary suggests 2026 biotech setup (undervaluation + M&A + less pricing focus) supportive of multiples.

Neutral/Negative Catalysts

- Near-term fundamental softness in profitability: latest quarter showed a swing to loss (see financials), which can cap rallies without a clear margin recovery path.
- Technical overhead: first resistance near 58.33 (R1); failure to clear can keep BMRN range-bound.
- Event-risk setup: options are pricing large moves (very high IV percentile), meaning post-event reaction can be decisive.
- No strong smart-money confirmation: hedge funds and insiders flagged as neutral (no strong accumulation signal).

Financial Performance

Latest reported quarter: 2025/Q3
- Revenue: $776.1M, +4.08% YoY → steady top-line growth, not explosive.
- Gross margin: 81.33%, +9.82% YoY → strong/improving product economics.
- Net income: -$30.7M (down -128.98% YoY) → profitability deteriorated versus prior year.
- EPS: -0.16 (down -129.09% YoY) → earnings power is the current weak spot despite revenue growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: improving/bullish
- 2026-01-27 Barclays: Overweight, PT $80 (positive biotech setup).
- 2026-01-20 Canaccord: Upgraded to Buy, PT $98 (expects Amicus deal to unlock sentiment/valuation).
- 2025-12-23 Truist: Buy, PT raised to $100 (deal seen accretive; long exclusivity runway).
- 2025-12-22 H.C. Wainwright: Neutral, PT $60 (sees payoff pushed into 2030s).
- 2025-12-03 Leerink: Downgrade to Market Perform, PT $60 (earlier skepticism).
Wall Street pros view: Amicus acquisition + commercial/pipeline updates could close a valuation gap; multiple firms see substantial upside vs current ~$57–58.
Wall Street cons view: some see the acquisition’s biggest payoff as longer-dated and Voxzogo remains the near-term focal point.
Influential/political trading: No recent congress trading data available; hedge funds/insiders reported neutral.

19 Analyst Rating

Wall Street analysts forecast BMRN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMRN is 87.35 USD with a low forecast of 60 USD and a high forecast of 120 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

14 Buy

5 Hold

0 Sell

Moderate Buy

Current: 57.150

Low

Averages

87.35

High

120

Current: 57.150

Low

Averages

87.35

High

120

Piper Sandler

Overweight -> NULL

downgrade

$122 -> $84

AI Analysis

2026-02-06

New

Reason

Piper Sandler

Price Target

$122 -> $84

AI Analysis

2026-02-06

New

downgrade

Overweight -> NULL

Reason

Piper Sandler lowered the firm's price target on BioMarin to $84 from $122 and keeps an Overweight rating on the shares. Following a number of Q4/FY25 pre-releases in recent weeks and ahead of Q4 reporting, the firm is taking the opportunity to review and adjust its estimates for some of its commercial names, as well as some price targets.

Barclays

Overweight

initiated

$80

2026-01-27

Reason

Barclays

Price Target

$80

2026-01-27

initiated

Overweight

Reason

Barclays assumed coverage of BioMarin with an Overweight rating and $80 price target. Barclays initiated coverage of 12 biotech stocks and assumed coverage of 11 with a positive view of the industry. The analyst likes the setup for the group in 2026. Many biotech stocks remain undervalued, the analyst tells investors in a research note. The firm expects continued mergers and acquisitions, "strong" underlying fundamentals, and less of a focus on drug pricing to act as "significant tailwinds."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BMRN

Unlock Now

BMRN Should I Buy

BMRN Should I Buy

Should You Buy BioMarin Pharmaceutical Inc (BMRN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch